Mirae Asset Global Investments Co. Ltd. Has $5.18 Million Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Mirae Asset Global Investments Co. Ltd. lowered its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 48.6% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 108,355 shares of the biopharmaceutical company’s stock after selling 102,613 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Ultragenyx Pharmaceutical were worth $5,182,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. UMB Bank n.a. boosted its position in Ultragenyx Pharmaceutical by 118.8% in the fourth quarter. UMB Bank n.a. now owns 606 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 329 shares in the last quarter. Covestor Ltd lifted its holdings in shares of Ultragenyx Pharmaceutical by 392.1% during the third quarter. Covestor Ltd now owns 748 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 596 shares during the period. Lazard Asset Management LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 36.6% during the first quarter. Lazard Asset Management LLC now owns 896 shares of the biopharmaceutical company’s stock worth $64,000 after purchasing an additional 240 shares during the period. International Assets Investment Management LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 3,182.4% during the fourth quarter. International Assets Investment Management LLC now owns 1,674 shares of the biopharmaceutical company’s stock worth $80,000 after purchasing an additional 1,623 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Ultragenyx Pharmaceutical by 97.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,831 shares of the biopharmaceutical company’s stock worth $65,000 after purchasing an additional 903 shares during the period. Institutional investors and hedge funds own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Trading Down 8.8 %

RARE opened at $42.87 on Tuesday. Ultragenyx Pharmaceutical Inc. has a 1-year low of $31.52 and a 1-year high of $54.98. The company has a market cap of $3.53 billion, a P/E ratio of -5.15 and a beta of 0.65. The company has a fifty day moving average price of $48.22 and a two-hundred day moving average price of $43.39.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.52) earnings per share for the quarter, beating the consensus estimate of ($1.65) by $0.13. Ultragenyx Pharmaceutical had a negative net margin of 139.70% and a negative return on equity of 369.54%. The firm had revenue of $127.39 million during the quarter, compared to the consensus estimate of $119.38 million. During the same period in the previous year, the firm posted ($2.16) earnings per share. The business’s revenue was up 23.3% compared to the same quarter last year. On average, research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -6.34 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently commented on RARE. Wedbush lifted their price target on shares of Ultragenyx Pharmaceutical from $47.00 to $48.00 and gave the stock a “neutral” rating in a report on Friday, February 16th. JPMorgan Chase & Co. lifted their price target on shares of Ultragenyx Pharmaceutical from $88.00 to $92.00 and gave the stock an “overweight” rating in a report on Monday, March 18th. Cantor Fitzgerald reiterated an “overweight” rating and set a $107.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, April 5th. Robert W. Baird lifted their price target on shares of Ultragenyx Pharmaceutical from $57.00 to $68.00 and gave the stock an “outperform” rating in a report on Tuesday, January 30th. Finally, Canaccord Genuity Group lifted their target price on shares of Ultragenyx Pharmaceutical from $110.00 to $111.00 and gave the stock a “buy” rating in a research note on Wednesday, February 21st. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, Ultragenyx Pharmaceutical presently has an average rating of “Moderate Buy” and an average target price of $91.55.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, EVP Thomas Richard Kassberg sold 11,509 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, March 11th. The shares were sold at an average price of $49.93, for a total value of $574,644.37. Following the completion of the sale, the executive vice president now directly owns 252,823 shares of the company’s stock, valued at $12,623,452.39. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, Director Matthew K. Fust sold 12,195 shares of the business’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $50.88, for a total transaction of $620,481.60. Following the completion of the sale, the director now directly owns 14,860 shares of the company’s stock, valued at $756,076.80. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Thomas Richard Kassberg sold 11,509 shares of the business’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $49.93, for a total transaction of $574,644.37. Following the sale, the executive vice president now directly owns 252,823 shares of the company’s stock, valued at $12,623,452.39. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 31,974 shares of company stock valued at $1,639,721. Corporate insiders own 6.80% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.